IL2 and neoplasm: Clinical evidence for an immune-mediated HD-IL-2 mechanism of action is based on tumor regression, the development of organ-specific autoimmunity in responders such as delayed-onset vitiligo, observed in some of our patients, and the onset of autoimmune thyroiditis.